AIM ImmunoTech reports positive mid-year Phase 2 data for Ampligen+Imfinzi in pancreatic cancer

AIM ImmunoTech Inc.

No grade ≥2 immune-related or systemic toxicities reported across 14 enrolled patients.
3 of 14 patients (21%) had PFS >6 months; 3 additional patients not yet progressed at cutoff.
Of 11 evaluable patients, 7 (64%) achieved overall survival >6 months.
Combination of Ampligen (rintatolimod) and AstraZeneca's Imfinzi (durvalumab) studied post-FOLFIRINOX.
Final analysis pending immune-monitoring data from paired biopsies and blood samples.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.